Innata Bio

Innata Bio (formerly CarthroniX) is a clinical-stage biotechnology company pioneering a new class of anti-inflammatory medicines that precisely control rather than shut down immune pathways. The company's platform focuses on developing first-in-class small molecule modulators of the IL-6/gp130 signaling axis, reducing harmful inflammation while preserving the regenerative and homeostatic signals essential for tissue repair. Its lead candidate, CX-011, is an intra-articular injectable suspension currently in Phase 1/2a clinical trials for the treatment of knee osteoarthritis, with preclinical data demonstrating both pain reduction and cartilage regeneration. Innata Bio is also advancing preclinical programs for idiopathic pulmonary fibrosis (IPF) and systemic cardiometabolic diseases, operating out of its headquarters at Lilly Gateway Labs in Philadelphia.